Anaptysbio (ANAB) Equity Average (2017 - 2026)

Anaptysbio has reported Equity Average for 10 years, with the latest figure at $25.0 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 52.37% year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (down 52.37% YoY), and the FY2025 full-year result was $54.0 million, down 32.01% from the prior year.
• Equity Average for Q1 2026 stood at $25.0 million, up from $3.9 million in the prior quarter.
• The five-year high for Equity Average was $343.6 million in Q1 2022, with the low at -$37.1 million in Q3 2025.
• Historically, Equity Average has averaged $124.6 million across 5 years, with a median of $77.6 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average retreated 11.75% — and 2025, when it slumped 178.68%.
• Anaptysbio's Equity Average stood at $269.9 million in 2022, then plunged by 61.37% to $104.2 million in 2023, then fell by 25.54% to $77.6 million in 2024, then tumbled by 94.98% to $3.9 million in 2025, then soared by 540.97% to $25.0 million in 2026.
• The last three Equity Average figures came in at $25.0 million (Q1 2026), $3.9 million (Q4 2025), and -$37.1 million (Q3 2025), per Business Quant data.